“Biotechs need flexibility and have limited budgets, while big pharma looks for long-term partnerships, reliability, scalability, and new technologies.”
Luis Berrade, Senior Director of Global Biologics Testing Sales at Charles River Laboratories, has spent his career helping pharmaceutical and biotech companies bring therapies to market faster and safer. With a PhD in medicinal chemistry and experience spanning both contract manufacturing and testing services, Luis now leads Charles River’s global biologics testing commercial strategy, working with companies of all sizes to navigate the complex regulatory landscape.
In an episode of the PharmaSource podcast, Luis shares his insights on when sponsors should start thinking about testing strategy, common mistakes that create bottlenecks, and how emerging technologies like next-generation sequencing are reshaping the biologics testing landscape.